News | November 12, 2007

Wright Medical Group Announces Japanese Regulatory Approval For Hip Resurfacing System

Arlington, TN - Wright Medical Group, Inc., a global orthopaedic medical device company, recently announced approval of its CONSERVE Plus Hip Resurfacing System by Japan's Ministry of Health, Labor and Welfare. Wright's CONSERVE Plus System will expand the treatment options Japanese surgeons may offer their patients by providing a conservative, anatomically-focused surgical alternative to traditional hip replacement.

Hip resurfacing with Wright's CONSERVE Plus System may be an ideal option for young, active patients suffering from chronic hip pain. In suitable patients, resurfacing allows the painful area of the hip joint to be surgically treated while retaining as much healthy bone as possible. Wright's CONSERVE Plus System also offers a wide range of sizing options and a larger-diameter femoral head which are designed to work together to help patients achieve a greater range of motion and a more natural gait postoperatively.

"It has been our corporate goal to introduce key technologies into the Japanese market. The CONSERVE Plus System is certainly one of those key technologies because it represents a significant alternative to total hip replacement and, thus, may offer a greater quality of life for some Japanese patients," explains Karen L. Harris, Wright's vice president of international sales and distribution. Mike Moritani, general manager of Wright Medical Japan, KK added, "The approval and launch of Wright's hip resurfacing device complements the innovations we have already introduced in this important market over the last year, which include our PROFEMUR Modular Hip System and our MICRONAIL Intramedullary Radial Fixation System."

Wright's CONSERVE Plus System is currently available in Europe, Canada, and Australia, as well as other international markets. The CONSERVE Plus System is not available in the United States at this time, while the Company's regulatory submission undergoes the U.S. FDA review process.

SOURCE: Wright Medical Group, Inc.